Inflammation and Immunity ELISA Panels & Biomarker Guide

In inflammation and immunology research, detecting a signal is not the challenge—the real difficulty lies in turning that signal into interpretable, comparable, and reproducible conclusions. The same phenotype can be driven by different pathways (innate recognition, chemotactic recruitment, effector immunity, negative feedback regulation, etc.) that alternately dominate, and the dominant factors can shift over time—which is why relying on a single indicator can easily lead to misinterpretation, while measuring too many indicators often makes the data difficult to decipher.

To help you more quickly translate your research questions into measurable indicator panels, we have broken down "inflammation and immunity" into eight high-frequency research topics based on common scientific workflows. Each topic follows the same framework: research question → Standard Panel (2 items) → Expanded Panel (3–5 items) → key interpretation points → classic references. You can use the Standard Panel to quickly answer directional questions and confirm the signaling axis and time window, then use the Expanded Panel for mechanistic stratification and cross-group comparisons, reducing the cost of trial and error.

Below, you can start from the research question you are addressing and, within one minute, locate the corresponding topic and recommended panel.

Standard Panel: 2 markers Expanded Panel: 3–5 markers Compatible sample types: serum/plasma, supernatant, tissue homogenate, lavage fluid Applicable scenarios: infection, oncology, intestinal disorders, efficacy/toxicology, autoimmunity

View the 8 Topics Quickly Select by Research Question Standard/Expanded Examples Why Choose CUSABIO FAQ

Research Question

First, select a topic based on your research question.

If you are unsure where to begin, we recommend first identifying the question you truly aim to answer, then accessing the corresponding topic to view the more complete panel, time point recommendations, and interpretation highlights.

Is inflammation initiated/amplified?Pro-inflammatory intensity, chemotactic recruitment, endothelial activation, acute phase. Is innate immunity triggered?PRR pathways, type I interferons, inflammasome-related clues. Is adaptive immunity established?Effector output, recruitment context, T/B response clues. Is there regulation/immune suppression?Checkpoint layer, insufficient effector function, suppressive environment. Has resolution and repair begun?Resolution signals, repair/remodeling, fibrosis risk. Mucosal barrier/Th17/IgA? Barrier integrity, Th17/IL-22, sIgA. Antibody response quality/durability?IgM→IgG/IgA, avidity, long-term titers. Too many signals and hard to interpret?Dominant axis → chemotaxis → checkpoint → risk of systemic hyperinflammation.

How to Use This Topic Center (3 Steps to Obtain Interpretable Results)

Step 1 – Select your research question:
First determine which of the three types of questions you aim to answer, such as "Is it initiated?", "Is there recruitment/amplification?", "Is it suppressed?", "Has it entered resolution/repair?", or "Are antibodies/mucosal defense established?".
Step 2 – Use the Standard Panel to define the direction:
First use the two most critical indicators to confirm "presence or absence", "strength", "which axis is involved", and "whether the time window is appropriate".
Step 3 – Use the Expanded Panel for stratification:
When you need to answer questions such as "Why is it stronger/weaker?", "Is there recruitment/amplification?", "Is a checkpoint layer present?", or "Is the response trending toward resolution?", add 1–3 mechanism-indicative markers and refer to the interpretation highlights and classic references on the topic page.

If you already have a model and sampling time points, after entering the topic page, prioritize reviewing the "Sample Types and Time Point Recommendations" – this can often significantly reduce trial and error.

Standard/Expanded Panel Examples

1) Is inflammation initiated & what is its intensity? (Corresponds to Topic 1/Topic 8)

Standard: TNF-α + IL-6

Expanded: TNF-α + IL-6 + IL-1β (± MCP-1)

Applicable for: early stages of stimulation/infection, stratification of pro-inflammatory background in efficacy/toxicology studies.

Go to Topic 1 Go to Topic 8

2) Does it lean toward the antiviral/nucleic acid sensing axis? (Corresponds to Topic 2)

Standard: IFN-β + CXCL10

Expanded: IFN-α + IFN-β + CXCL10 (± IL-6)

Applicable for: viral infection/nucleic acid stimulation/PRR-related models; first determine whether a type I interferon and IFN-driven chemokine background is present.

Go to Topic 2

3) Does chemotactic recruitment occur and is it potentially amplified? (Corresponds to Topic 1/Topic 8)

Standard: MCP-1(CCL2) + CXCL10

Expanded: CCL2 + CXCL10 + IL-6 (± TNF-α / IL-8)

Applicable for: when you suspect an infiltration/recruitment-driven phenotype, combining chemokine and inflammatory intensity readouts provides greater robustness.

Go to Topic 1 Go to Topic 8

4) Is there a "checkpoint layer/negative feedback"? (Corresponds to Topic 4/Topic 5/Topic 8)

Standard: IL-10 + IL-1RA

Expanded: IL-10 + IL-1RA + TGF-β1 (± TNF-α)

Applicable for: post-peak decline phase, stratification of immunosuppression/regulation; it is recommended to interpret in conjunction with pro-inflammatory background.

Go to Topic 4 Go to Topic 5 Go to Topic 8

5) Is the mucosal defense axis activated? (Corresponds to Topic 6)

Standard: IL-17A + IL-22

Expanded: IL-17A + IL-22 + IL-23 (± IL-1β)

Applicable for: mucosal-associated models such as intestinal or respiratory tract; first localize using the "defense axis", then add barrier/inflammation/IgA pathway components as needed.

Go to Topic 6

6) Is humoral immunity transitioning from early to mature stages? (Corresponds to Topic 7)

Standard: Antigen-specific IgM + Antigen-specific IgG

Expanded: + IgG subclasses (species-dependent) or + avidity (e.g., via avidity ELISA)

Applicable for: vaccine/infection/immunization regimen comparisons; first assess kinetics (initiation → maturation), then evaluate bias and qualitative clues.

Go to Topic 7

8 Major Topics

Inflammation Initiation and Amplification

Confirm whether inflammation is initiated, whether it is amplified through chemotactic recruitment, and the readout pathway for key amplification steps.

Standard: TNF-α + IL-6
Expanded: + IL-1β / MCP-1 / (endothelial or acute phase-related readouts, see topic page)

Pro-inflammatory intensityChemotactic recruitmentAmplification steps

Go to Topic 1

Innate Immune Activation

Determine whether the stimulus is recognized by PRRs and triggers the pro-inflammatory/interferon axis, suitable for infection and immune stimulation models.

Standard: TNF-α + IL-6 or IFN-β + CXCL10
Expanded: + IL-1β / IFN-α (depending on model)

PRR pathwaysType I interferonsEarly response

Go to Topic 2

Adaptive Immune Response

Focuses on combined readouts of effector output and recruitment context, to be interpreted in conjunction with antibody response (Topic 7).

Standard: IL-2 + IFN-γ
Expanded: + CXCL10 / CCL5 (depending on research objective)

Effector outputRecruitment contextMechanistic stratification

Go to Topic 3

Immune Regulation and Immunosuppression

Distinguish between "resolution/regulation" and "effector suppression"; suitable for pharmacodynamics and chronic inflammation stratification.

Standard: IL-10 + IL-1RA (or IL-10 + TGF-β1)
Expanded: Add pro-inflammatory background or effector indicators for combined interpretation (see topic page)

Checkpoint layerInsufficient effector functionSuppressive environment

Go to Topic 4

Inflammation Resolution and Tissue Repair

Provides a continuous readout pathway from "resolution → repair → remodeling → fibrosis risk", suitable for mid-to-late stage interpretation.

Standard: IL-10 + IL-1RA (resolution clues)
Expanded: VEGF / MMP-9 + TIMP-1 / PDGF-BB (depending on the question)

ResolutionRepairRemodelingRisk stratification

Go to Topic 5

Mucosal Immunity

Focuses on forming a closed-loop readout around barrier integrity, mucosal inflammation axis, Th17/IL-22, and IgA/sIgA defense.

Standard: IL-17A + IL-22 or sIgA + pIgR/SC
Expanded: + IL-23 / LBP + sCD14 (depending on the pathway)

IgATh17/IL-22Barrier

Go to Topic 6

Humoral Immunity and Antibody Response

Provides a readout pathway from kinetics (IgM → IgG) to bias/quality (subclass, avidity) and durability.

Standard: Specific IgM + Specific IgG
Expanded: IgG subclasses / avidity / IL-21 (depending on capability)

KineticsBiasQuality cluesDurability

Go to Topic 7

Cytokine Network and Immune Communication

When numerous indicators are difficult to interpret, use the "dominant axis → chemotaxis → checkpoint → systemic risk" framework to translate results into conclusions.

Standard: TNF-α + IL-6 (dominant axis) or CCL2 + CXCL10 (chemotaxis)
Expanded: IL-10 + IL-1RA / IL-6 + IFN-γ (depending on objective)

Network interpretation frameworkStratified comparisonRisk alert

Go to Topic 8

Why Choose CUSABIO ELISA Kit?

More comprehensive coverage, convenient for panel creation

Common species (Human/Mouse/Rat) are comprehensively covered, and support forPig/Bovine/Dog/Rabbit, etc.Multi-species, suitable for cross-model and cross-species comparative studies.

Quality control is more clearly defined

Validation was conducted around key indicators such as detection range, sensitivity, specificity, linearity, recovery rate, and intra-/inter-batch precision, resulting in more stable and reproducible outcomes. (Click to view the 8 major quality control standards of CUSABIO ELISA kits.)

Sample compatibility is broader

Supports common sample types such as serum/plasma, cell supernatant, tissue homogenate/lysate, and adapts to different reading requirements from "initiation" to "systemic acute phase."

Ready-to-use for greater convenience

Complete facilities and standardized processes reduce preparation work and human error.

Global Customer Recognition

Currently, CUSABIO products have reached customers worldwide, with product citations in literature.Over 30, 000 articles, some published in Nature,Cell、Cell research、 High-impact journals such as Immunity. (Click to view CUSABIO 30000+ product citation literature)

FAQ

Q: Which topic should I start with? +

A: If you can describe your purpose in one sentence:

"Is inflammation present or how strong is it?" → Topic 1
"Is the innate recognition/IFN axis triggered?" → Topic 2
"Is effector immunity established?" → Topic 3
"Is there regulation/suppression?" → Topic 4
"Has resolution/repair/fibrosis risk begun?" → Topic 5
"Mucosal barrier/Th17/IgA" → Topic 6
"Are antibodies generated, and what is their quality and durability?" → Topic 7
"Many indicators but difficult to interpret" → Topic 8

Q: What research objectives are the Standard Panel (2 items) and Expanded Panel (3–5 items) suitable for? +

A: Standard: Used to quickly answer directional questions (presence or absence, strength, which axis, whether the time window is appropriate).

Expanded: Used for mechanistic stratification and cross-group comparisons (why stronger/weaker, whether recruitment/checkpoint/repair trends exist).

Q: Is it acceptable to collect samples at only one time point? +

A: It is acceptable, but more suitable for screening/preliminary assessment. If your goal is mechanistic interpretation or conclusions at a publication level, we recommend at least 2–3 time points to observe trends; otherwise, results may be affected by missing peak responses or axis shifts.

Q: Should I prioritize serum/plasma, or cell supernatant/tissue homogenate? +

A: Choose based on your objective:

For mechanism and stimulus comparison: Supernatant is clearer (source is more defined).
For systemic intensity and cohort stratification: Serum/plasma is more appropriate.
For local microenvironment/tissue outcomes (repair, mucosa): Tissue homogenate/lavage fluid is more sensitive.

(The topic page provides guidance on which sample types are recommended for answering specific research questions.)

Q: Why is it not recommended to measure many indicators at the start? +

A: Because the cytokine network exhibits redundancy and time dependence: a large panel often yields results showing that "many things have changed," yet remains difficult to answer the core question. A more robust approach is: first localize the axis with Standard → then add key mechanistic indicators with Expanded.

Q: If I want the most reliable conclusions with minimal cost, what should I choose? +

A: Prioritize selecting two items that directly address your question:

Initiation/intensity: TNF-α + IL-6 (example)
Chemotactic recruitment: CCL2 + CXCL10 (example)
Checkpoint layer: IL-10 + IL-1RA (example)

Then add 1–3 expanded items based on the "cause" you need to explain.

Q: If I see elevated IL-10 (or TGF-β), can I directly conclude that "inflammation is resolving" or "immunity is suppressed"? +

A: It is not recommended to draw conclusions from a single indicator. IL-10/TGF-β are more like "checkpoint/regulatory clues"; they must be interpreted together with the pro-inflammatory background (e.g., IL-6/TNF) or effector output to distinguish between "resolution" and "suppression."

Q: How can I avoid misinterpreting "local inflammation" as "systemic inflammation"? +

A: The key lies in sample type and controls: tissue homogenate reflects local conditions more closely, while serum/plasma reflects systemic conditions. We recommend retaining at least one systemic readout or including control groups, and prioritizing trends over single time point values.

Q: If the results show that "none of the indicators changed much," what are the common reasons? +

A: Common reasons include: the time point missed the window, insufficient stimulation intensity, sample processing/matrix interference, or the model itself exhibits a weak response. We recommend returning to the time point recommendations on the topic page and rerunning the Standard Panel at 1–2 key time windows.

Q: If the results show that "many indicators are elevated,"" how can I quickly organize this into an interpretable conclusion? +

A: Organize in the following order:

Dominant axis (intensity) → Chemotactic recruitment (amplification) → Checkpoint layer (regulation) → Outcome/risk (repair or systemic hyperinflammation).

This is the interpretation framework of Topic 8, which can transform "many changes" into a pathway narrative.

Q: When should I consider upgrading ELISA findings with combined validation? +

A: When you aim to draw stronger conclusions (e.g., "a certain pathway dominates" or "a certain cellular event occurs"), we recommend integrating functional endpoints (pathology, burden, scoring) and necessary cellular/histological or molecular evidence. ELISA is better suited for providing trends and mechanistic clues.

Q: How can I improve comparability when results fluctuate across batches or experiments? +

A: Keep the "Standard core readouts" fixed, standardize the key time points and sample processing workflows; use Expanded indicators only when needed to explain differences. Additionally, within the same project, maintain a fixed panel combination to minimize variables.

Disclaimer: This document is a compilation of information for research purposes only. ELISA results are intended to provide trends and mechanistic clues; key conclusions should be drawn by integrating model endpoints and, where necessary, cellular/histological evidence for comprehensive assessment.

ELISA Series--Inflammation and Immunity